ARGENX SE
ARGX · FY2024
CEO Package
$0
Pay Ratio
—
Tim Van Hauwermeiren
Awaiting a fuller pay-performance history
Cidara Therapeutics, Inc.
CDTX · FY2024
CEO Package
$6.0M
Pay Ratio
—
Jeffrey Stein
Awaiting a fuller pay-performance history
Revolution Medicines, Inc.
RVMD · FY2025
CEO Package
$14.7M
Pay Ratio
—
Mark A. Goldsmith
Pay and TSR both rose, but not in lockstep
All values are grant-date fair value as reported in proxy statements.
The fastest way to read this comparison before dropping into the tables.
Latest CEO package mix by company. This stays on the CEO package even if the chart above is showing Top 5 pay.
ARGX
Tim Van Hauwermeiren
$0
CDTX
Jeffrey Stein
$6.0M
RVMD
Mark A. Goldsmith
$14.7M
| Company | CEO | Latest Year | Total Comp |
|---|---|---|---|
| ARGENX SE(ARGX) | N/A | N/A | N/A |
| Cidara Therapeutics, Inc.(CDTX) | Jeffrey Stein | 2024 | $6.0M |
| Revolution Medicines, Inc.(RVMD) | Mark A. Goldsmith | 2025 | $14.7M |
Note: All compensation values shown are grant-date fair value as reported in proxy statements. Direct comparisons should account for differences in company size, industry, and compensation structure.
Want to know when these numbers change?
We’ll email you when these companies file a new proxy — so you can see how CEO pay, equity awards, and ratios shift before the next headline.